Literature DB >> 10769638

Response to 5-fluorouracil of orthotopically xenografted human colon cancers with a microsatellite instability: influence of P53 status.

M Pocard1, R Bras-Gonçalves, R Hamelin, J Northover, M F Poupon.   

Abstract

Response to 5-FU of 5 different human colon cancers (hCC) with a DNA microsatellite instability (MSI), xenografted into nude mice, was analysed according to their p53 status. Two hCC (TC82 and TC71) had a mutated p53 (mutp53), while two others (TC33 and LoVo) had a wild type p53 (wtp53); the fifth tumour (X17LoVo) originated from the stable transfection of LoVo cells with a dominant mutp53 (273his) vector. All tumours were implanted onto the caecum of nude mice to induce orthotopic growth of hCC. 5-FU was administered at 40 mg/kg per day for 5 consecutive days. A significant growth inhibition of TC82 and TC71 tumours (of 68 and 60%, p < 0.05 and < 0.01 respectively) was observed, whereas 5-FU had no effect on TC33 and LoVo. Moreover, the mutp53 transfected tumour, X17LoVo, displayed significant sensitivity to 5-FU (p < 0.05). This suggests that distinct genetic alterations influence differently the response of hCC to this antimetabolite.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10769638

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  13 in total

1.  Molecular pathways: microsatellite instability in colorectal cancer: prognostic, predictive, and therapeutic implications.

Authors:  Frank A Sinicrope; Daniel J Sargent
Journal:  Clin Cancer Res       Date:  2012-02-02       Impact factor: 12.531

2.  Regulation of MLH1 mRNA and protein expression by promoter methylation in primary colorectal cancer: a descriptive and prognostic cancer marker study.

Authors:  Lars Henrik Jensen; Anders Aamann Rasmussen; Lene Byriel; Hidekazu Kuramochi; Dorthe Gylling Crüger; Jan Lindebjerg; Peter V Danenberg; Anders Jakobsen; Kathleen Danenberg
Journal:  Cell Oncol (Dordr)       Date:  2013-09-12       Impact factor: 6.730

3.  Prognostic impact of deficient DNA mismatch repair in patients with stage III colon cancer from a randomized trial of FOLFOX-based adjuvant chemotherapy.

Authors:  Frank A Sinicrope; Michelle R Mahoney; Thomas C Smyrk; Stephen N Thibodeau; Robert S Warren; Monica M Bertagnolli; Garth D Nelson; Richard M Goldberg; Daniel J Sargent; Steven R Alberts
Journal:  J Clin Oncol       Date:  2013-09-09       Impact factor: 44.544

4.  Microsatellite instability in colorectal cancer: from molecular oncogenic mechanisms to clinical implications.

Authors:  Aziz Zaanan; Katy Meunier; Fatiha Sangar; Jean-François Fléjou; Françoise Praz
Journal:  Cell Oncol (Dordr)       Date:  2011-04-12       Impact factor: 6.730

5.  Doxorubicin and octreotide induce a 40 kDa breakdown product of p53 in human hepatoma and tumoral colon cell lines.

Authors:  Zahia Sadji-Ouatas; Malika Lasfer; Sophie Julien; Gérard Feldmann; Florence Reyl-Desmars
Journal:  Biochem J       Date:  2002-06-15       Impact factor: 3.857

Review 6.  Chemotherapy of MMR-deficient colorectal cancer.

Authors:  N Devaud; S Gallinger
Journal:  Fam Cancer       Date:  2013-06       Impact factor: 2.375

Review 7.  Prognosis in DNA mismatch repair deficient colorectal cancer: are all MSI tumours equivalent?

Authors:  A J Clark; R Barnetson; S M Farrington; M G Dunlop
Journal:  Fam Cancer       Date:  2004       Impact factor: 2.375

8.  5-fluorouracil (5FU) treatment does not influence invasion and metastasis in microsatellite unstable (MSI-H) colorectal cancer.

Authors:  Janindra Warusavitarne; Palaniappan Ramanathan; Anthony Kaufman; Bruce G Robinson; Margaret Schnitzler
Journal:  Int J Colorectal Dis       Date:  2006-03-24       Impact factor: 2.571

Review 9.  Mismatch repair deficient colorectal cancer in the era of personalized treatment.

Authors:  Madeleine Hewish; Christopher J Lord; Sarah A Martin; David Cunningham; Alan Ashworth
Journal:  Nat Rev Clin Oncol       Date:  2010-02-23       Impact factor: 66.675

10.  MSH3 mismatch repair protein regulates sensitivity to cytotoxic drugs and a histone deacetylase inhibitor in human colon carcinoma cells.

Authors:  Jae Myung Park; Shengbing Huang; David Tougeron; Frank A Sinicrope
Journal:  PLoS One       Date:  2013-05-28       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.